Brivaracetam is an analogue of levetiracetam that is Food and Drug Administration-approved for adjunctive treatment of partial-onset seizures in patients 16 years and older.
Objective: The aim of this study was to evaluate the efficacy, tolerability, and retention of brivaracetam (BRV) in genetic generalized epilepsy (GGE) in real-life practice.
Objectives: To assess first clinical experiences with brivaracetam (BRV) in the treatment of epilepsies.
Currently, a number of novel anticonvulsant drugs, the so-called third generation, are in various stages of development. Several of them are already available or in ongoing clinical trials.
Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults.
UCB has announced regulatory milestones in the US and the EU for its investigational antiepileptic drug brivaracetam ( proposed trade...
UCB has announced positive topline results from the latest Phase III study with brivaracetam. This study was designed to evaluate...
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
UCB announced the primary efficacy and safety data from the latest Phase III study evaluating Rikelta (brivaracetam) (fixed doses of...
Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.